FLXN - Flexion Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Currency in USD

Valuation Measures

Market Cap (intraday) 5
535.02M
Enterprise Value 3
528.38M
Trailing P/E
N/A
Forward P/E 1
-5.73
PEG Ratio (5 yr expected) 1
N/A
Price/Sales (ttm)
12.15
Price/Book (mrq)
12.90
Enterprise Value/Revenue 3
11.99
Enterprise Value/EBITDA 6
-3.51

Trading Information

Stock Price History

Beta (3Y Monthly) 1.22
52-Week Change 3-24.05%
S&P500 52-Week Change 38.19%
52 Week High 319.55
52 Week Low 38.76
50-Day Moving Average 313.73
200-Day Moving Average 311.85

Share Statistics

Avg Vol (3 month) 3614.01k
Avg Vol (10 day) 3550.33k
Shares Outstanding 538.11M
Float 33.28M
% Held by Insiders 11.98%
% Held by Institutions 1115.18%
Shares Short (Sep 30, 2019) 48.52M
Short Ratio (Sep 30, 2019) 414.18
Short % of Float (Sep 30, 2019) 429.00%
Short % of Shares Outstanding (Sep 30, 2019) 422.35%
Shares Short (prior month Aug 30, 2019) 48.96M

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor (new per old) 2N/A
Last Split Date 3N/A

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 31, 2018
Most Recent Quarter (mrq)Jun 30, 2019

Profitability

Profit Margin 0.00%
Operating Margin (ttm)-343.90%

Management Effectiveness

Return on Assets (ttm)-31.83%
Return on Equity (ttm)-142.96%

Income Statement

Revenue (ttm)44.05M
Revenue Per Share (ttm)1.16
Quarterly Revenue Growth (yoy)346.50%
Gross Profit (ttm)15.19M
EBITDA -150.41M
Net Income Avi to Common (ttm)-162.24M
Diluted EPS (ttm)-4.28
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)171.57M
Total Cash Per Share (mrq)4.5
Total Debt (mrq)164.94M
Total Debt/Equity (mrq)397.71
Current Ratio (mrq)7.80
Book Value Per Share (mrq)1.09

Cash Flow Statement

Operating Cash Flow (ttm)-156.76M
Levered Free Cash Flow (ttm)-99.91M